e-learning
resources
Milan 2017
Sunday, 10.09.2017
The spectrum of CTDs: from pathogenesis to treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Extensive interstitial lung disease in inflammatory myopathy is a strong predictor of mortality
D. Assayag (Montréal, QC, Canada)
Source:
International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Session:
The spectrum of CTDs: from pathogenesis to treatment
Session type:
Thematic Poster
Number:
890
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Assayag (Montréal, QC, Canada). Extensive interstitial lung disease in inflammatory myopathy is a strong predictor of mortality. 890
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Using the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Frequency and impact of interstitial lung disease on clinical state and mortality in systemic scleroderma
Source: Annual Congress 2012 - Diffuse parenchymal lung disease III
Year: 2012
The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype
Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018
Year: 2018
Variation in mortality from interstitial lung disease by diagnosis
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Radiologic pattern as a survival predictor in the rheumatoid artritis intersticial lung disease
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016
Prognostic factors of interstitial lung disease associated with primary Sjögren's syndrome
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Study of factors affecting mortality in ILD cases over 2 years
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016
Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent
Source: Eur Respir J, 55 (4) 1901519; 10.1183/13993003.01519-2019
Year: 2020
Predictors of progression in systemic sclerosis patients with interstitial lung disease
Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019
Year: 2020
The analysis of prognostic factors in patients with interstitial lung diseases
Source: International Congress 2015 – New insights into IIPs
Year: 2015
Co-morbidities and cause of death in patients with rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Potential causes of acute deterioration in patients with interstitial lung disease
Source: Annual Congress 2010 - Different patterns of interstitial lung disease
Year: 2010
Rituximab in severe, progressive interstitial lung disease
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Overall survival is significantly higher in sarcoidosis than in IPF patients after lung transplantation
Source: Annual Congress 2013 –Clinical studies in lung transplantation
Year: 2013
Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease?
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept